Prospective Grant of Exclusive License: Diagnostics of Fungal Infections, 53105 [E6-14872]

Download as PDF Federal Register / Vol. 71, No. 174 / Friday, September 8, 2006 / Notices Control and Prevention (CDC), Technology Transfer Office, Department of Health and Human Services (DHHS), is contemplating the grant of a limited field of use, exclusive license in India to practice the inventions embodied in the patent referred to below to Molecular Diagnostic Laboratory, having a place of business in Lucknow, India. The patent rights in these inventions have been assigned to the government of the United States of America. The patent(s) to be licensed are: US 6,896,892 B2 entitled ‘‘InsecticideImpregnated Fabric and Method of Production,’’ issue date 05.24.2005. CDC Technology ID No. I–008–99. Status: Issued. Issue Date: 05.24.2005 The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. Technology: This technology provides a new insecticide-impregnated fabric and method of production for bednets. In accordance with 35 U.S.C. 209(e) and 37 CFR 404.7(a)(1)(i), CDC is providing public notice of its intention to grant an exclusive license. CDC will accept written comments concerning this notice for 30 days. Applications for a license filed in response to this notice will be treated as objections to the grant of the contemplated license. Only written comments and/or applications for a license which are received by CDC within thirty days of this notice will be considered. Comments and objections submitted in response to this notice will not be made available for public inspection, and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552. SUPPLEMENTARY INFORMATION: Requests for a copy of this patent, inquiries, comments, and other materials relating to the contemplated license should be directed to Suzanne Seavello Shope, J.D., Technology Licensing and Marketing Specialist, Technology Transfer Office, Centers for Disease Control and Prevention (CDC), 4770 Buford Highway, Mailstop K–79, Atlanta, GA 30341, telephone: (770) 488–8613; facsimile: (770) 488–8615. sroberts on PROD1PC70 with NOTICES ADDRESSES: Dated: August 31, 2006. James D. Seligman, Chief Information Officer, Centers for Disease Control and Prevention. [FR Doc. E6–14871 Filed 9–7–06; 8:45 am] BILLING CODE 4163–18–P VerDate Aug<31>2005 19:38 Sep 07, 2006 Jkt 208001 DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention Prospective Grant of Exclusive License: Diagnostics of Fungal Infections Technology Transfer Office, Centers for Disease Control and Prevention (CDC), Department of Health and Human Services. ACTION: Notice. AGENCY: SUMMARY: This is a notice in accordance with 35 U.S.C. 209(e) and 37 CFR 404.7(a)(1)(i) that the Centers for Disease Control and Prevention (CDC), Technology Transfer Office, Department of Health and Human Services (DHHS), is contemplating the grant of a worldwide, limited field of use, coexclusive license to practice the inventions embodied in the patent and patent applications referred to below to Myconostica, Inc. (Myconostica) having a place of business in Manchester, United Kingdom. CDC intends to grant no more than three licenses to these inventions. The patent rights in these inventions have been assigned to the government of the United States of America. The patent and patent applications to be licensed are: Title: Nucleic Acids for Detecting Aspergillus Species and Other Filamentous Fungi. U.S. Patent Application Serial No.: 09/423,233. Filing Date: 6/27/2000. Domestic Status: 6,372,430. Issue Date: 4/16/2002. Title: Molecular Identification of Aspergillus Species. U.S. Patent Application Serial No.: 60/381,463. Filing Date: 5/17/2002. Domestic Status: Pending. Issue Date: N/A. Title: Nucleic Acids for the Identification of Fungi and Methods for Using the Same. U.S. Patent Application Serial No.: 60/325,241. Filing Date: 9/26/2001. Domestic Status: Pending. Issue Date: N/A. The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. Specific DNA (oligonucleotide) probes have been developed for a wide variety of systemic disease causing fungi, including Aspergillus species and others. A probe has been developed for identification of all dimorphic fungi. PO 00000 Frm 00030 Fmt 4703 Sfmt 4703 53105 These probes can be used for the rapid identification of fungal pathogens and for the diagnosis of mycotic diseases. ADDRESSES: Requests for a copy of these patent applications, inquiries, comments, and other materials relating to the contemplated license should be directed to Andrew Watkins, Director, Technology Transfer Office, Centers for Disease Control and Prevention (CDC), 4770 Buford Highway, Mailstop K–79, Atlanta, GA 30341, telephone: (770) 488–8610; facsimile: (770) 488–8615. Applications for a license filed in response to this notice will be treated as objections to the grant of the contemplated license. Only written comments and/or applications for a license which are received by CDC within sixty days of this notice will be considered. Comments and objections submitted in response to this notice will not be made available for public inspection, and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552. A signed Confidential Disclosure Agreement will be required to receive a copy of any pending patent application. Dated: August 31, 2006. James D. Seligman, Chief Information Officer, Centers for Disease Control and Prevention. [FR Doc. E6–14872 Filed 9–7–06; 8:45 am] BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. 2006N–0349] Risk Communication on Medical Devices: Sharing Perspectives AGENCY: Food and Drug Administration, HHS. ACTION: Notice of public meeting. SUMMARY: The Food and Drug Administration (FDA), in cooperation with the Advanced Medical Technology Association (AdvaMed), is announcing a public meeting entitled ‘‘Risk Communication on Medical Devices: Sharing Perspectives.’’ This 1-day workshop is intended to bring together various creators and recipients of medical device risk/benefit information to discuss how this information is developed, disseminated, and perceived; and to explore ways in which the process might be improved. DATES AND TIMES: The public meeting will be held on September 26, 2006, from 7:30 a.m. to 5 p.m. Online registration is available until 5 p.m. on E:\FR\FM\08SEN1.SGM 08SEN1

Agencies

[Federal Register Volume 71, Number 174 (Friday, September 8, 2006)]
[Notices]
[Page 53105]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E6-14872]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Prospective Grant of Exclusive License: Diagnostics of Fungal 
Infections

AGENCY: Technology Transfer Office, Centers for Disease Control and 
Prevention (CDC), Department of Health and Human Services.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is a notice in accordance with 35 U.S.C. 209(e) and 37 
CFR 404.7(a)(1)(i) that the Centers for Disease Control and Prevention 
(CDC), Technology Transfer Office, Department of Health and Human 
Services (DHHS), is contemplating the grant of a worldwide, limited 
field of use, co-exclusive license to practice the inventions embodied 
in the patent and patent applications referred to below to Myconostica, 
Inc. (Myconostica) having a place of business in Manchester, United 
Kingdom. CDC intends to grant no more than three licenses to these 
inventions. The patent rights in these inventions have been assigned to 
the government of the United States of America. The patent and patent 
applications to be licensed are:
    Title: Nucleic Acids for Detecting Aspergillus Species and Other 
Filamentous Fungi.
    U.S. Patent Application Serial No.: 09/423,233.
    Filing Date: 6/27/2000.
    Domestic Status: 6,372,430.
    Issue Date: 4/16/2002.

    Title: Molecular Identification of Aspergillus Species.
    U.S. Patent Application Serial No.: 60/381,463.
    Filing Date: 5/17/2002.
    Domestic Status: Pending.
    Issue Date: N/A.

    Title: Nucleic Acids for the Identification of Fungi and Methods 
for Using the Same.
    U.S. Patent Application Serial No.: 60/325,241.
    Filing Date: 9/26/2001.
    Domestic Status: Pending.
    Issue Date: N/A.
    The prospective exclusive license will be royalty-bearing and will 
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7.
    Specific DNA (oligonucleotide) probes have been developed for a 
wide variety of systemic disease causing fungi, including Aspergillus 
species and others. A probe has been developed for identification of 
all dimorphic fungi. These probes can be used for the rapid 
identification of fungal pathogens and for the diagnosis of mycotic 
diseases.

ADDRESSES: Requests for a copy of these patent applications, inquiries, 
comments, and other materials relating to the contemplated license 
should be directed to Andrew Watkins, Director, Technology Transfer 
Office, Centers for Disease Control and Prevention (CDC), 4770 Buford 
Highway, Mailstop K-79, Atlanta, GA 30341, telephone: (770) 488-8610; 
facsimile: (770) 488-8615. Applications for a license filed in response 
to this notice will be treated as objections to the grant of the 
contemplated license. Only written comments and/or applications for a 
license which are received by CDC within sixty days of this notice will 
be considered. Comments and objections submitted in response to this 
notice will not be made available for public inspection, and, to the 
extent permitted by law, will not be released under the Freedom of 
Information Act, 5 U.S.C. 552. A signed Confidential Disclosure 
Agreement will be required to receive a copy of any pending patent 
application.

    Dated: August 31, 2006.
James D. Seligman,
Chief Information Officer, Centers for Disease Control and Prevention.
 [FR Doc. E6-14872 Filed 9-7-06; 8:45 am]
BILLING CODE 4163-18-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.